1. Home
  2. SGP vs VALN Comparison

SGP vs VALN Comparison

Compare SGP & VALN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

SGP

SpyGlass Pharma Inc. Common Stock

N/A

Current Price

$18.67

Market Cap

650.9M

Sector

Health Care

ML Signal

N/A

Logo Valneva SE

VALN

Valneva SE

HOLD

Current Price

$5.40

Market Cap

536.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SGP
VALN
Founded
2019
2012
Country
United States
France
Employees
65
N/A
Industry
Medical/Dental Instruments
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
650.9M
536.9M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
SGP
VALN
Price
$18.67
$5.40
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
5
2
Target Price
$45.00
$15.50
AVG Volume (30 Days)
41.0K
38.1K
Earning Date
05-15-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$93.87
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$17.60
$5.06
52 Week High
$30.56
$12.25

Technical Indicators

Market Signals
Indicator
SGP
VALN
Relative Strength Index (RSI) 34.50 39.25
Support Level N/A $5.11
Resistance Level $26.29 $6.60
Average True Range (ATR) 1.52 0.27
MACD -0.20 -0.02
Stochastic Oscillator 20.34 5.26

Price Performance

Historical Comparison
SGP
VALN

About SGP SpyGlass Pharma Inc. Common Stock

SpyGlass Pharma Inc is a late-stage biopharmaceutical company focused on transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. The company is developing two programs: the BIM-IOL System, which is intended for use during cataract surgery to deliver glaucoma treatment, and the BIM-DRS, which is designed for glaucoma patients who are not undergoing cataract surgery.

About VALN Valneva SE

Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.

Share on Social Networks: